Abstract
Context
The pathogenesis of diabetic nephropathy (DN) is still incompletely understood. Few studies have linked the cellular inflammatory markers, interleukin 6 (IL-6) and highly sensitive C-reactive protein (hs-CRP), to the development of DN.
Aim
We aimed to explore the link among IL-6, hs-CRP, and grades of DN in both types of diabetes mellitus (DM).
Settings and design
We carried out a case–control study on participants selected from the outpatient clinic of Internal Medicine Department.
Patients and methods
We worked on 91 participants, comprising 78 patients and 13 controls. The patient group was further subdivided into two subgroups: subgroup I [39 patients type 1 DM (T1DM)] and subgroup II [39 patients type 2 DM (T2DM)]. Each subgroup was categorized according to the urinary albumin excretion rate into three divisions: A (<20 μg/min), B (20–200 μg/min), and C (>200 μg/min). We applied history taking, clinical examination, routine investigation, and IL-6 with hs-CRP testing to all participants.
Statistical analysis
We used Shapiro–Wilk test, χ2 test, Student’s t test, one-way analysis of variance, Kruskal–Wallis test, least significant difference test, and Pearson’s correlation coefficient for data analysis.
Results
Despite the significant difference of laboratory data between patient and control groups, least significant difference analysis revealed a nonsignificant difference between patients with T1DM and those with T2DM. On the level of the in-groups analysis, the most significant key players were hs-CRP and IL-6 among the three urinary albumin excretion rate categories of patients with T1DM and T2DM, with P values less than 0.01.
Conclusions
We concluded that IL-6 and hs-CRP might be used as sensitive markers for the development of DN.
Article PDF
Similar content being viewed by others
References
Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res 2015; 2015:948417.
Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci 2002; 99:13043–13048.
Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012; 8: 1227–1236.
Avci E, Çakir E, Cevher SC, Yaman H, Agilli M, Bilgi C. Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. Ren Fail 2014; 36: 767–773.
Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16(Suppl 1): S78–S82.
Choudhary N, Ahlawat RS. Interleukin-6 and C-Reactive protein in pathogenesis of diabetic nephropathy new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis 2008; 2:72–79.
Czyzewska J, Wasilewska K, Kamińska J, Koper O, Kemona H, Jakubowska I. Assess the impact of concentrations of inflammatory markers IL-6, CRP in the presence of albuminuria in patients with type 2 diabetes. Pol Merkur Lekarski 2012; 32:98–102.
Shelbaya S, Amer H, Seddik S, Allah AA, Sabry IM, Mohamed T, et al. Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. Eur Rev Med Pharmacol Sci 2012; 16:176–182.
Domingueti CP, Fóscolo RB, Reis JS, Campos FM, Dusse LM, Carvalho MD, et al. Association of haemostatic and inflammatory biomarkers with nephropathy in type 1 diabetes mellitus. J Diabetes Res 2016; 2016: 2315260.
Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG, et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010; 33:804–810.
Wang X, Bao W, Liu J, OuYang YY, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013; 36:166–175.
Schwab KO, Doerfer J, Hecker W, Grulich-Henn J, Wiemann D, Kordonouri O, et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006; 29: 218–225.
Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm 2006; 2006:2315260.
Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD, EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes – the EURODIAB Prospective Complications Study. Diabetologia 2005; 48:370–378.
Piccirillo LJ, Gonçalves MD, Clemente EL, Gomes MD. Markers of inflammation in type 1 diabetic patients. Arq Bras Endocrinol Metabol 2004; 48:253–260.
Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51:1157–1165.
Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, et al. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care 2005; 28:1051–1056.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Abdelnabi, A.M., Sadek, A.M.E.M. Role of interleukin 6 and highly sensitive C-reactive protein in diabetic nephropathy. Egypt J Intern Med 30, 103–109 (2018). https://doi.org/10.4103/ejim.ejim_27_18
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/ejim.ejim_27_18